
    
      Approximately 420 subjects with inadequately controlled T2DM on metformin will be recruited
      from North America and Europe. Subjects will be randomly assigned to receive bexagliflozin
      tablets, 20 mg, or glimepiride capsules, 2, 4 or 6 mg, in a ratio of 1:1 once daily for 96
      weeks. Subjects will continue to take metformin for the duration of the study.
    
  